News and Insights from Our Multidisciplinary Team of Experts
Roger Pearce is an Image Analysis Services Manager at Flagship Biosciences. Through expertise in Image Analysis and Digital Pathology, Pearce and his team strive to solve problems for both internal and external clients, pushing their skills and technology to their...
Dr. Henderson is Vice President of Computational & Imaging Sciences at Flagship. With a passion for innovative technology and solving problems for clients, Dr. Henderson not only inspires his team but also pushes the boundaries of what’s possible in our industry....
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...
Genomenon’s genomic landscapes enhance Flagship’s biomarker services and companion diagnostic development solutions
Broomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced a strategic partnership…
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Author(s): Maria Szwarc, Ph.D., Flagship Biosciences, Inc., Chandler S. Callaway, Ph.D., Flagship Biosciences, Inc., G. Dave Young, DVM, Flagship Biosciences, Inc., Nathaniel H. Atwood, B.S., Flagship Biosciences, Inc., Will Paces, MAS, Flagship Biosciences, Inc.,...
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
EVENTS
Meet us at the 2nd annual Spatial Biology for Drug Development Summit. We’re excited to be a Program Partner for the Spatial Biology for Drug Development Summit, returning to Boston for a 2nd year, October 22-24. This year, we’ll dive into the latest in spatial omics...
Meet with us in Boston for World CB & CDx.We’re thrilled to be a Spotlight Partner for the 14th World Clinical Biomarkers and Companion Diagnostics Summit. Join us there to exchange insights with biotech and pharma leaders, researchers, and scientists and to discuss...
Meet with us at booth #25. As a Gold Sponsor for the third annual Spatial Biology East Coast Congress in Boston, we hope you’ll join our experts and over 350 other industry leaders to discuss the transforming field of spatial biology. Examine how spatial biology can...